Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Total Valuation
Autolus Therapeutics has a market cap or net worth of $369.94M. The enterprise value is $617.39M.
Market Cap$369.94M
Enterprise Value$617.39M
Share Statistics
Autolus Therapeutics has 266,143,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding266,143,280
Owned by Insiders―
Owned by Institutions40.17%
Financial Efficiency
Autolus Therapeutics’s return on equity (ROE) is -1.61 and return on invested capital (ROIC) is -53.08%.
Return on Equity (ROE)-1.61
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-53.08%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee116.79K
Profits Per Employee-444.40K
Employee Count647
Asset Turnover0.13
Inventory Turnover2.90
Valuation Ratios
The current PE Ratio of Autolus Therapeutics is ―. Autolus Therapeutics’s PEG ratio is -0.08.
PE Ratio―
PS Ratio7.01
PB Ratio2.97
Price to Fair Value2.97
Price to FCF-1.75
Price to Operating Cash Flow-1.30
PEG Ratio-0.08
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 75.56M and earned -287.53M in profits. Earnings per share was -1.08.
Revenue75.56M
Gross Profit-21.03M
Operating Income-281.44M
Pretax Income-296.85M
Net Income-287.53M
EBITDA-271.60M
Earnings Per Share (EPS)-1.08
Cash Flow
In the last 12 months, operating cash flow was -283.57M and capital expenditures -23.76M, giving a free cash flow of -307.33M billion.
Operating Cash Flow-283.57M
Free Cash Flow-307.33M
Free Cash Flow per Share-1.15
Dividends & Yields
Autolus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.44
52-Week Price Change17.80%
50-Day Moving Average1.48
200-Day Moving Average1.69
Relative Strength Index (RSI)46.70
Average Volume (3m)1.86M
Important Dates
Autolus Therapeutics upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Autolus Therapeutics as a current ratio of 5.94, with Debt / Equity ratio of 197.38%
Current Ratio5.94
Quick Ratio5.48
Debt to Market Cap0.54
Net Debt to EBITDA-0.91
Interest Coverage Ratio-7.66
Taxes
In the past 12 months, Autolus Therapeutics has paid 1.97M in taxes.
Income Tax1.97M
Effective Tax Rate>-0.01
Enterprise Valuation
Autolus Therapeutics EV to EBITDA ratio is -2.86, with an EV/FCF ratio of -2.56.
EV to Sales10.28
EV to EBITDA-2.86
EV to Free Cash Flow-2.56
EV to Operating Cash Flow-2.74
Balance Sheet
Autolus Therapeutics has $300.71M in cash and marketable securities with $351.59M in debt, giving a net cash position of -$50.88M billion.
Cash & Marketable Securities$300.71M
Total Debt$351.59M
Net Cash-$50.88M
Net Cash Per Share-$0.19
Tangible Book Value Per Share$0.59
Margins
Gross margin is -27.84%, with operating margin of -372.45%, and net profit margin of -380.51%.
Gross Margin-27.84%
Operating Margin-372.45%
Pretax Margin-392.84%
Net Profit Margin-380.51%
EBITDA Margin-359.43%
EBIT Margin-372.45%
Analyst Forecast
The average price target for Autolus Therapeutics is $8.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.40
Price Target Upside504.32% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast407.86%
EPS Growth Forecast30.35%